Curve Dental vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cloud dental practice management software offering an all-in-one platform for single offices and growing dental groups. Layton UT; founded 2004; one of the earliest true cloud dental PMS alternatives to legacy Dentrix and Eaglesoft; no local server required; covers scheduling, charting, imaging, and billing.
About
Curve Dental is a Layton, Utah-based cloud-based dental practice management software company that offers an all-in-one platform combining scheduling, clinical charting, digital imaging, billing, and patient communication in a single browser-based application. Founded in 2004, Curve was among the early movers in cloud dental practice management and has built a platform specifically for independent dental practices and small group practices that want a modern, easy-to-use alternative to legacy on-premise systems like Dentrix and Eaglesoft. Curve's cloud architecture means there is no local server to maintain, no software to install or update, and no data backup to manage—the entire system is accessed through a web browser from any device with an internet connection.\n\nCurve's integrated imaging capability—including digital X-ray sensor compatibility, intraoral camera support, and panoramic image management—is a key differentiator in the cloud practice management market, where many competitors require a separate imaging software. By managing clinical imaging and scheduling in the same platform, Curve eliminates the need to switch between systems during patient appointments and ensures that radiographs are automatically associated with the correct patient chart and treatment records. The platform's clinical charting module supports periodontal charting, treatment planning, electronic prescriptions, and clinical notes in a unified workflow designed for the pace of a busy dental office.\n\nCurve Dental competes with Dentrix Ascend (Henry Schein's cloud offering), Eaglesoft Cloud, Carestream, and Planet DDS's Denticon in the dental practice management market. The company targets single-office practices and small groups of up to 10 locations that want cloud convenience without the enterprise complexity of DSO-focused platforms. Curve differentiates on the all-in-one nature of its platform—imaging included at no additional cost—and the simplicity of its pricing and onboarding experience for practices transitioning from legacy systems.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.